TP53 and neoplasm: Translational analyses from the MITO16A/MaNGO OV‐2 program, highlight challenges such as assay standardisation, multiplicity correction and external validation, while identifying tumour immune infiltration patterns, TP53 mutation classes and composite HRD assessments as areas of further investigation.